Predictors for symptom improvement in overactive bladder patients treated with imidafenacin

The objective of this investigation is to ascertain the determinants associated with the amelioration of symptoms in female patients suffering from overactive bladder (OAB) following treatment with 0.2 mg of imidafenacin. The study included 66 female OAB patients who had been prescribed a daily dose of 0.2 mg imidafenacin for a minimum of 3 months, spanning from March 2018 to June 2020. Various clinical parameters including age, coexistence of additional voiding symptoms, prior history of urological surgeries, and responses to the Overactive Bladder Symptom Score questionnaire (OABSS), both pre- and post-initiation of imidafenacin therapy, were evaluated. The mean total OABSS scores recorded before and 3 months subsequent to imidafenacin therapy were 8.36 ± 3.65 and 5.15 ± 3.22, respectively. Following the 3-month course of imidafenacin treatment, there was a statistically significant improvement in both the total OABSS score and the severity of OAB symptoms (p < 0.001 for both). Prior to treatment initiation, Group B (n = 38) exhibited significantly higher total OABSS scores and subscores compared to Group A (n = 28) (p < 0.05). Multivariable analysis identified the OABSS subscores for items 1 and 3 prior to treatment as significant predictors for the improvement of OAB severity subsequent to imidafenacin therapy (p = 0.046, OR 3.10, 95% CI 1.019–9.440 and p < 0.001, OR 2.77, 95% CI 1.671–4.587, respectively). Consequently, imidafenacin emerges as an efficacious therapeutic agent for alleviating OAB severity in female patients, with the OABSS subscores for items 1 and 3 prior to treatment initiation holding potential utility in predicting the efficacy of imidafenacin in managing OAB.